Linked Life Data

2464793

Source:http://linkedlifedata.com/resource/pubmed/id/2464793

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5-6
pubmed:dateCreated
1989-3-16
pubmed:abstractText
Recent developments in experimental chemotherapy may benefit patients with chronic lymphocytic leukemia (CLL). Fludarabine monophosphate has shown promise in heavily pretreated patients with advanced CLL. The Southwest Oncology Group has recently completed a phase II investigation of fludarabine in 32 patients. The patient population had a median age of 63 years, median performance status of 1, and included patients with the following stages of the disease: stage 0-3 patients; stage I-5 patients; stage II-6 patients; stage III-4 patients; stage IV-14 patients. A total of 176 courses were administered. Myelosuppression was the most frequent toxicity observed with 13 patients having a decline in platelets, and 11 patients having some decline in granulocytes. Fludarabine monophosphate has had unequivocal antileukemic activity in a group of patients with advanced CLL.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:author
pubmed:volume
30
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
457-9
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.
pubmed:affiliation
Ohio State University, Division of Hematology/Oncology, Columbus 43210.
pubmed:publicationType
Journal Article